![](https://www.biopharmadive.com/imgproxy/Ht25pBdDPQF4yKcRR_Ee8FwSyXzqh9kpbCMyP22qAWo/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE3NDEzMDg1MTguanBn.jpg)
J&J bets bigger on MeiraGTx’s eye gene therapy
Dive Brief: Gene therapy developer MeiraGTx is selling its remaining financial interest in an eye-disease treatment partnered with Johnson &
Read MoreJuly 2, 2024
Dive Brief: Gene therapy developer MeiraGTx is selling its remaining financial interest in an eye-disease treatment partnered with Johnson &
Read MoreDive Brief: Clene Nanomedicine on Thursday said the Food and Drug Administration doesn’t believe the company has gathered enough evidence
Read MoreDive Brief: Argenx lost a quarter of its value Wednesday after reporting the second research setback in two months for
Read MoreDive Brief: GSK is deepening its investment in cancer treatments called antibody-drug conjugates, announcing Wednesday plans to pay $185 million
Read MoreDive Brief: Shares of UniQure dipped more than 10% Tuesday morning after the biotechnology company released more data from a
Read MoreDive Brief: DNA sequencing company Illumina said Sunday it will divest Grail, the liquid biopsy maker it fought to hang
Read MoreDive Brief: The Novo Nordisk Foundation, which owns a controlling stake in drugmaker Novo Nordisk, said Monday it will invest
Read MoreDive Brief: Venture capital group Pivotal Life Sciences has raised its second fund, securing $389 million to invest in young
Read MoreDive Brief: Vir Biotechnology on Thursday announced a restructuring that will result in a 12% reduction in its workforce as
Read MoreAmgen has a new top scientist, announcing Thursday the appointment of Novartis veteran and prolific biotechnology startup founder Jay Bradner
Read More